Clinically, several studies have reported the role of MALT1 in reflecting treatment response to conventional synthetic disease‐modifying antirheumatic drugs and tumor necrosis factor (TNF) inhibitors in several autoimmune disease patients, including Crohn's disease (CD), rheumatoid arthritis (RA), and ankylosing spondylitis (AS).17, 18, 19, 20. This evidence concerns the gene TNF and autoimmune disease.